{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:59:51Z","timestamp":1780693191251,"version":"3.54.1"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>\n                    We present a 63-year-old man with a history of prostate adenocarcinoma (mCRPC), widespread skeletal and multiple lymph node metastases, who was referred for\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA therapy. In second course of therapy, posttreatment scan showed multiple foci of increased activity throughout the liver, compatible with diffuse hepatic metastases, which were not seen in the diagnostic and the first posttreatment scans and SPECT\/CT images. This unexpected finding turned the case into a clinical dilemma, leaving the medical team uncertain about how best to proceed to ensure the most appropriate care. Eventually, a liver FNA confirmed the presence of metastatic prostatic adenocarcinoma.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006170","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:00:25Z","timestamp":1780689625000},"page":"e487-e489","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Sudden Diffuse Hepatic Metastases After First 177Lu-PSMA Cycle in Bone Predominant mCRPC Patient"],"prefix":"10.1097","volume":"51","author":[{"given":"Mohammad Hadi","family":"Samadi","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Nuclear Medicine Research Center, Mashhad University of Medical Science, Mashhad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Forouzanian","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Sahafi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Nuclear Medicine Research Center, Mashhad University of Medical Science, Mashhad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Jafari Zarrin Ghabaei","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Nuclear Medicine Research Center, Mashhad University of Medical Science, Mashhad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atena","family":"Aghaee","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Nuclear Medicine Research Center, Mashhad University of Medical Science, Mashhad"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"R1-20260605","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1007\/s00259-023-06326-w","article-title":"Early biochemical and radiographic response after one cycle of [177Lu] Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients","volume":"50","author":"Cytawa","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R2-20260605","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00259-023-06536-2","article-title":"Early response monitoring during [177Lu] Lu-PSMA I&T therapy with quantitated SPECT\/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study","volume":"51","author":"Neubauer","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R3-20260605","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/RLU.0000000000003044","article-title":"FDG hepatic superscan due to metastatic infiltration of prostate cancer","volume":"45","author":"Yildirim","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R4-20260605","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.2967\/jnumed.121.263441","article-title":"Outcome of patients with PSMA PET\/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis","volume":"63","author":"Hotta","year":"2022","journal-title":"J Nucl Med"},{"key":"R5-20260605","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/ERC-18-0226","article-title":"Neuroendocrine differentiation of prostate cancer leads to PSMA suppression","volume":"26","author":"Bakht","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"R6-20260605","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.3390\/cancers13143607","article-title":"Target heterogeneity in oncology: the best predictor for differential response to radioligand therapy in neuroendocrine tumors and prostate cancer","volume":"13","author":"Puranik","year":"2021","journal-title":"Cancers"},{"key":"R7-20260605","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/RLU.0000000000001419","article-title":"68Ga-DOTATOC and 68Ga-PSMA PET\/CT unmasked a case of prostate cancer with neuroendocrine differentiation","volume":"41","author":"Chen","year":"2016","journal-title":"Clin Nucl Med"},{"key":"R8-20260605","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1097\/RLU.0000000000003685","article-title":"Prostate cancer with neuroendocrine differentiation recurring after treatment with 177Lu-PSMA: a chance for 177Lu-DOTATATE therapy?","volume":"46","author":"Javan","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R9-20260605","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/RLU.0000000000002013","article-title":"Adenocarcinoma prostate with neuroendocrine differentiation: potential utility of 18F-FDG PET\/CT and 68Ga-DOTANOC PET\/CT over 68Ga-PSMA PET\/CT","volume":"43","author":"Parida","year":"2018","journal-title":"Clin Nucl Med"},{"key":"R10-20260605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/RLU.0000000000001424","article-title":"PET\/CT with 68Ga-DOTA-TATE for diagnosis of neuroendocrine: differentiation in patients with castrate-resistant prostate cancer","volume":"42","author":"Gofrit","year":"2017","journal-title":"Clin Nucl Med"},{"key":"R11-20260605","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2967\/jnumed.123.265874","article-title":"PSMA PET\/CT for response assessment and overall survival prediction in patients with metastatic castration-resistant prostate cancer treated with androgen receptor pathway inhibitors","volume":"64","author":"Shagera","year":"2023","journal-title":"J Nucl Med"},{"key":"R12-20260605","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2967\/jnumed.121.261906","article-title":"Tumor sink effect in 68Ga-PSMA-11 PET: myth or reality?","volume":"63","author":"Gafita","year":"2022","journal-title":"J Nucl Med"},{"key":"R13-20260605","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/RLU.0000000000003515","article-title":"Occult bone metastases from hepatocellular carcinoma detected on 68Ga-PMSA PET\/CT","volume":"46","author":"Usmani","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R14-20260605","first-page":"1097","article-title":"Radionuclide therapy with 177Lu-PSMA in a patient with hepatocellular carcinoma","volume":"10","author":"Pretet","year":"2022","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:00:27Z","timestamp":1780689627000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006170","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"2025-06-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}